These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 24115837

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PCSK9: From discovery to therapeutic applications.
    Farnier M.
    Arch Cardiovasc Dis; 2014 Jan; 107(1):58-66. PubMed ID: 24373748
    [Abstract] [Full Text] [Related]

  • 7. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
    Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MS.
    Clin Cardiol; 2012 Jan; 35(7):385-91. PubMed ID: 22714699
    [Abstract] [Full Text] [Related]

  • 8. PCSK9: a key modulator of cardiovascular health.
    Seidah NG, Awan Z, Chrétien M, Mbikay M.
    Circ Res; 2014 Mar 14; 114(6):1022-36. PubMed ID: 24625727
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM, Dorsch MP, Bleske BE.
    Pharmacotherapy; 2013 Apr 14; 33(4):447-60. PubMed ID: 23553812
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HM, Jackson S.
    J Lipid Res; 2014 Nov 14; 55(11):2370-9. PubMed ID: 25258384
    [Abstract] [Full Text] [Related]

  • 15. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD, Kim JB, Wasserman SM, Lambert G.
    Pharmacol Ther; 2015 Jan 14; 145():58-66. PubMed ID: 25046268
    [Abstract] [Full Text] [Related]

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.
    PLoS One; 2013 Jan 14; 8(5):e64145. PubMed ID: 23675525
    [Abstract] [Full Text] [Related]

  • 17. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G, Qian YW, Kowala MC, Konrad RJ.
    Endocr Metab Immune Disord Drug Targets; 2008 Dec 14; 8(4):238-43. PubMed ID: 19075777
    [Abstract] [Full Text] [Related]

  • 18. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK, Jensen HK.
    Ugeskr Laeger; 2015 Mar 09; 177(11):. PubMed ID: 25786699
    [Abstract] [Full Text] [Related]

  • 19. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH, O'Reilly P, Lu C, Gomes J, Lagace TA, Basak A.
    Eur J Med Chem; 2015 Mar 06; 92():890-907. PubMed ID: 25679794
    [Abstract] [Full Text] [Related]

  • 20. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L, Robinson JG.
    Prog Cardiovasc Dis; 2015 Mar 06; 58(1):19-31. PubMed ID: 25936907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.